Population genetic structure of variable drug response

被引:322
作者
Wilson, JF
Weale, ME
Smith, AC
Gratrix, F
Fletcher, B
Thomas, MG
Bradman, N
Goldstein, DB
机构
[1] UCL, Dept Biol, Galton Lab, London, England
[2] Univ Oxford, Dept Zool, Oxford OX1 3PS, England
[3] UCL, Dept Biol, Ctr Genet Anthropol, London, England
[4] Genost Ltd, London WC1A 2HN, England
关键词
D O I
10.1038/ng761
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Geographic patterns of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, indicate that geographic structuring of inter-individual variation in drug response may occur frequently. This raises two questions: how to represent human population genetic structure in the evaluation of drug safety and efficacy, and how to relate this structure to drug response. We address these by (i) inferring the genetic structure present in a heterogeneous sample and (ii) comparing the distribution of DME variants across the inferred genetic clusters of individuals. We find that commonly used ethnic labels are both insufficient and inaccurate representations of the inferred genetic clusters, and that drug-metabolizing profiles, defined by the distribution of DME variants, differ significantly among the clusters. We note, however, that the complexity of human demographic history means that there is no obvious natural clustering scheme, nor an obvious appropriate degree of resolution. Our comparison of drug-metabolizing profiles across the inferred clusters establishes a framework for assessing the appropriate level of resolution in relating genetic structure to drug response.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 21 条
  • [1] A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene:: association with tardive dyskinesia in schizophrenia
    Basile, VS
    Özdemir, V
    Masellis, M
    Walker, ML
    Heltzer, HY
    Lieberman, JA
    Potkin, SG
    Alva, G
    Kalow, W
    Macciardi, FM
    Kennedy, JL
    [J]. MOLECULAR PSYCHIATRY, 2000, 5 (04) : 410 - 417
  • [2] Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
    Bernal, ML
    Sinues, B
    Johansson, I
    McLellan, RA
    Wennerholm, A
    Dahl, ML
    Ingelman-Sundberg, M
    Bertilsson, L
    [J]. PHARMACOGENETICS, 1999, 9 (05): : 657 - 660
  • [3] MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS
    BLUM, M
    DEMIERRE, A
    GRANT, DM
    HEIM, M
    MEYER, UA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5237 - 5241
  • [4] Daly D. A., 1993, American Journal of Speech-Language Pathology, V2, P6, DOI [10.1044/1058-0360.0202.06, DOI 10.1044/1058-0360.0202.06]
  • [5] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491
  • [6] Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356
  • [7] NAD(P)H:quinone oxidoreductase:: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations
    Gaedigk, A
    Tyndale, RF
    Jurima-Romet, M
    Sellers, EM
    Grant, DM
    Leeder, JM
    [J]. PHARMACOGENETICS, 1998, 8 (04): : 305 - 313
  • [8] Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
    Gaedigk, A
    Gotschall, RR
    Forbes, NS
    Simon, SD
    Kearns, GL
    Leeder, JS
    [J]. PHARMACOGENETICS, 1999, 9 (06): : 669 - 682
  • [9] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
    Goldstein, JA
    Blaisdell, J
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 210 - 218
  • [10] IDENTIFICATION OF THE PRIMARY GENE DEFECT AT THE CYTOCHROME-P450 CYP2D LOCUS
    GOUGH, AC
    MILES, JS
    SPURR, NK
    MOSS, JE
    GAEDIGK, A
    EICHELBAUM, M
    WOLF, CR
    [J]. NATURE, 1990, 347 (6295) : 773 - 776